Summary & Overview
HCPCS J7310: Ganciclovir 4.5 mg Long-Acting Intraocular Implant
HCPCS Level II code J7310 designates a 4.5 mg long-acting ganciclovir implant for intraocular antiviral therapy. The code captures a drug-device formulation intended for sustained release within the eye and is relevant to ophthalmology services addressing viral retinal disease. Nationally, this code matters because it represents a high-cost, procedure-associated pharmaceutical product with implications for medical benefit coverage, facility billing, and specialty practice workflows.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for intraocular antiviral implants, payer coverage considerations, common modifiers used with drug and procedure billing, and where this HCPCS code sits in service lines for ophthalmology and ambulatory surgical care. The publication summarizes typical sites of service and the service type associated with the code, outlines what payer coverage categories are commonly relevant, and highlights the types of benchmarks and policy updates that affect utilization and reimbursement for long-acting intraocular drug implants.
This summary is intended for national audiences including billing managers, revenue cycle professionals, and clinical leaders seeking a concise reference for HCPCS Level II code J7310 and its role in ophthalmic drug-device billing.
Billing Code Overview
HCPCS Level II code J7310 describes Ganciclovir, 4.5 mg, long-acting implant. This code represents the drug implant formulation of ganciclovir used for sustained intraocular delivery.
Service Type: Intraocular long-acting antiviral implant placement
Typical Site of Service: Ophthalmology clinic or ambulatory surgical setting (intraocular procedure site)
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with sight‑threatening cytomegalovirus (CMV) retinitis or a recurrent viral retinitis in an immunocompromised patient who requires sustained intraocular antiviral therapy. The service involves insertion of a long‑acting intraocular ganciclovir implant (J7310, ganciclovir, 4.5 mg, long‑acting implant) placed in the vitreous cavity by an ophthalmic surgeon. Workflow: preoperative evaluation in a retina clinic, informed consent and review of systemic immunosuppression status, perioperative ophthalmic and systemic medication reconciliation, operating room placement of the implant under local or general anesthesia, postoperative topical antibiotics and antiinflammatory drops, scheduled retinal examinations to monitor implant position, retinal status, intraocular pressure, and systemic antiviral therapy coordination with the patient’s infectious disease or transplant team. Typical site of service is an ambulatory surgery center or hospital outpatient operating room with ophthalmic microsurgical capability.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or complexity substantially exceeds usual for implant insertion (document justification). |